December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Anti-VEGF Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Phase IB Results
Author Affiliations & Notes
  • LJ SingermanEyeTech Study Group
    Cleveland OH
  • Footnotes
    Commercial Relationships    L.J. Singerman, EyeTech Pharmaceuticals, Inc. C, R.
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 2908. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      LJ SingermanEyeTech Study Group; Anti-VEGF Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Phase IB Results . Invest. Ophthalmol. Vis. Sci. 2002;43(13):2908.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Research suggests that anti-vascular endothelial growth factor (VEGF) therapy may be useful in the treatment of ocular neovascularization. A Phase IA study of a single intravitreal injection of anti-VEGF in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) revealed a good safety profile. To determine the safety profile of multiple-injection therapy, we performed a Phase IB study of multiple injections of anti-VEGF, with or without photodynamic therapy (PDT), in patients with subfoveal CNV secondary to AMD. Methods: A Phase IB multiple-dose study of intravitreal injection of the drug, with or without PDT, was performed in 21 patients with subfoveal CNV secondary to AMD. Results: There were no significant safety issues related to the drug. Ophthalmic evaluation 3 months after treatment showed that 87.5% of patients who received only the anti-VEGF aptamer showed stable or improved vision and that 25% demonstrated a 3-line or greater improvement in vision on the ETDRS chart. A 3-line gain at 3 months was observed in 60% of patients who received both the anti-VEGF aptamer and photodynamic therapy. Conclusion: Anti-VEGF therapy is a promising treatment of neovascularization secondary to various ocular diseases, including AMD. In this Phase IB study, multiple intravitreal injections of the anti-VEGF aptamer were well tolerated, and visual results were very encouraging. Further clinical trials are required, and a Phase III study to evaluate the efficacy and long-term safety of this treatment is currently underway at 115 centers in the USA and abroad.

Keywords: 346 choroid: neovascularization • 308 age-related macular degeneration • 423 growth factors/growth factor receptors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×